Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
1. Novo Nordisk’s Rybelsus shows 14% lower cardiovascular risks in diabetes patients. 2. Rybelsus trials involve over 9,600 patients aged 50 and older. 3. Approval for expanded use of Rybelsus is pending in the U.S. and EU. 4. Patients prefer oral medication options over injectable treatments. 5. Rybelsus has shown consistent results across various patient demographics.